Menu

Recent Interviews

Alison Coutts, Executive Chairman, Memphasys Ltd.

Alison Coutts
Executive Chairman | Memphasys Ltd.
30 Richmond Road, 2140 Homebush West (AUS)

alison.coutts@memphasys.com

+61 2 8415 7300

Memphasys Executive Chairman Alison Coutts on in vitro fertilisation (IVF)


Thomas Soltau, CEO, wallstreet:online capital AG

Thomas Soltau
CEO | wallstreet:online capital AG
Michaelkirchstraße 17/18, 10179 Berlin (D)

service@smartbroker.de

+49 30 27 57 76 464

Smartbroker - wallstreet:online capital AG CEO Thomas Soltau in an interview on the market launch


Jonathan Summers, CEO, EXMceuticals Inc.

Jonathan Summers
CEO | EXMceuticals Inc.
1111 Alberni Street, Suite 1603, V6E 4V2 Vancouver (CAN)

jonathan@exmceuticals.com

EXMceuticals CEO Jonathan Summers on the medical cannabis market


23. October 2019 | 07:54 CET

AURORA, BEVCANNA, EXMCEUTICALS - CANADA GETTING READY FOR CANNABIS 2.0

  • Cannabis

The consulting firm Deloitte has taken a close look at the cannabis industry and evaluated food and extracted products for the cannabis 2.0 market. In their analysis, the experts came to the conclusion that the annual Canadian market for food and alternative cannabis products is worth CAD 2.7 billion. The vast majority of this emerging cannabis 2.0 market will be products based on cannabis extracts, including foods, which the analysis puts at CAD 1.6 billion alone. But there are other significant opportunities, including cannabis-infused beverages with CAD 529 million, health products with CAD 174 million, concentrates with CAD 140 million, tinctures with CAD 116 million and capsules with CAD 114 million.

time to read: 1 minutes by Mario Hose


Jonathan Summers, CEO, EXMceuticals Inc.
"[...] In being able to grow in some of the best natural conditions in the world along the equator, Africa offers enormous advantages for cannabis cultivation. [...]" Jonathan Summers, CEO, EXMceuticals Inc.

Zum Interview


Meet decision makers in your locality on
www.meet-the-management.com

Subscribe now

 

LEGALIZATION PROVIDES FOUNDATION FOR NEW MARKETS

The realisation of this considerable market potential will take some time, according to the Deloitte experts, because many cannabis products in these categories will only be available in sufficient quantities over time. Deloitte's industry representatives see cannabis 2.0 as a catalyst for the Canadian market, which is divided into two different target groups, in the context of further legalisation in October 2019.

Firstly, experienced cannabis users, such as millennials and younger people, already consume cannabis several times a week and are open to new products.

NEW CONSUMER GROUPS OFFER POTENTIAL

As the second target group of a new cannabis boom, the Deloitte experts see the beginners and the curious. Usually they are not interested in flammable cannabis. This new conservative type of user, typically middle-aged and university educated, focuses on family needs or other responsibilities and consumes cannabis less than once a month.

These consumers are expected to be attracted to more familiar formats, particularly foods such as baked goods, confectionery and teas. The low doses available in food and micro-doses are ideal for these consumers and provide a more convenient starting point for their cannabis experience.

NEW COMPANIES OFFER FAVOURABLE VALUATIONS

The outlined development of the cannabis 2.0 market becomes interesting in connection with the increasing legalization of cannabis products around the globe and against this background not only the first series like Aurora and Canopy Growth are exciting, but also the innovative new players with interesting business models or cost-efficient structures. In recent years, the young companies have been able to learn from the weaknesses and strengths of the already established billion-euro companies.

BevCanna Enterprises Inc., a developer and manufacturer of cannabinoid-based beverages and consumer goods for private labels and white label customers, is just as interesting as EXMceuticals Inc., a company that produces CBD of the highest quality in various African countries and wants to offer it in large quantities worldwide. The two companies are currently valued at less than CAD 50 million on the stock exchange. Jonathan Summers, Chairman of EXMceuticals, will present the company this year at the German Equity Forum in Frankfurt. If Deloitte's market assessment proves to be true and this trend continues globally, then these two companies will certainly be attractively valued from today's perspective. We will see.


Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold shares in the aforementioned companies and that there may therefore be a conflict of interest. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

23. March 2020 | 15:00 CET

Aurora Cannabis, Bayer, EXMceuticals - ready for the time after Corona

  • Cannabis

The cannabis hype was over and then came the corona crisis. Investors who believed in the active ingredient of cannabis and put money into the shares of companies in this industry are now likely to be sitting on a huge loss in most cases. It all started with the idea of a few companies to make one of the oldest medicinal plants in the world acceptable for general use within the framework of legalization. However, high margins and a large market soon led to competition and a brokerage industry was earning a lot of money - soon several hundred cannabis companies were listed on the stock exchange.

Read

25. February 2020 | 13:38 CET

Aurora Cannabis, Canopy Growth, EXMceuticals - who will be the best turnaround story?

  • Cannabis

Cannabis shares are not in demand at the moment. About a year ago the growth potential and possibilities of the rediscovered historical medicinal plant seemed to be endless. Today it is different, there is a hangover mood. The hype back then led to a buyer's market. Investors underbid each other with purchase orders and shareholders surrendered their shares in a nervous mood in order to set off for new shores. This or something similar may be the current situation in the environment of numerous cannabis companies. But experienced investors also know that consolidation phases are the foundation for success stories.

Read

11. February 2020 | 14:55 CET

Aphria, Canopy Growth, EXMceuticals - Europe becomes the largest cannabis market

  • Cannabis

The consulting firm Prohibition Partners expects Europe to grow into the world's largest market for legal cannabis products in the next five years. Germany will become by far the largest market for medical cannabis products. According to the experts, Europe will thus overtake the North American market.

Read